Cargando…

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

BACKGROUND: Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons. OBJECTIVE: To determine whether inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Y, Takeuchi, T, Mimori, T, Saito, K, Nawata, M, Kameda, H, Nojima, T, Miyasaka, N, Koike, T
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015067/ https://www.ncbi.nlm.nih.gov/pubmed/20360136 http://dx.doi.org/10.1136/ard.2009.121491

Ejemplares similares

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019)

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
por: Kaneko, Yuko, et al.
Publicado: (2018)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
por: Hirata, Shintaro, et al.
Publicado: (2013)

RRR…
por: de Beer, Tineke
Publicado: (2021)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
por: Takeuchi, Tsutomu, et al.
Publicado: (2009)

RRR evaluation of niobium using AC susceptibility measurement
por: Wake, M, et al.
Publicado: (1996)

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
por: Tanaka, Yoshiya, et al.
Publicado: (2008)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review
por: Nahra, Vicky, et al.
Publicado: (2020)

Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study
por: Hu, Huiqin, et al.
Publicado: (2017)

Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission
por: Kameda, Hideto, et al.
Publicado: (2021)

Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines
por: Campbell, Sharon E, et al.
Publicado: (2006)

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade(®))
por: Kim, Soohyun, et al.
Publicado: (2020)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
por: Reinisch, Walter, et al.
Publicado: (2017)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

A method to evaluate RRR of superconducting cavities
por: D'Elia, D
Publicado: (2012)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Twenty Years of Quiescence after Nonstop Remicade(®) (Infliximab) Infusions in a Child with Ocular Behçet Disease Presenting as Hypopyon-Anterior Uveitis Refractory to Immunosuppressants
por: Evereklioglu, Cem
Publicado: (2023)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
por: Atsumi, Tatsuya, et al.
Publicado: (2017)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n83j8e2ursochd36pb2onlrsmo